Novel dual-use peptidase inhibitors as prodrugs for a...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 277/06 (2006.01) A61K 31/427 (2006.01) A61P 25/00 (2006.01) C07D 295/18 (2006.01) C07D 417/12 (2006.01)

Patent

CA 2628145

The invention relates to compounds of the general formulae (1) and (2) A - B - D - B' - A' (1) and A - B - D - E (2), in which A and A' may be identical or different and are the radical (I) in which X is S, O, CH2, CH2CH2, CH2O or CH2NH, and Y is H or CN, and * designates a chiral carbon atom, preferably in the S or L configuration; B and B' may be identical or different and are an O- , N- or S-containing or non-O-, N- or S-containing, unsubstituted or substituted, unbranched or branched alkylene radical, cycloalkylene radical, aralkylene radical, heterocycloalkylene radical, heteroarylalkylene radical, arylamidoalkylene radical, heteroarylamidoalkylene radical, unsubstituted or mono- or polysubstituted arylene radical or heteroarylene radical having one or more five-, six- or seven-membered ring(s); D is -S-S- or -Se-Se-; and E is the group -CH2-CH(NH2)-R9 or -CH2-*CH(NH2)-R9in which R9 is an O-, N- or S- containing or non-O-, N- or S-containing, unsubstituted or substituted, unbranched or branched alkyl radical, cycloalkyl radical, aralkyl radical, heterocycloalkyl radical, heteroarylalkyl radical, arylamidoalkyl radical, heteroarylamidoalkyl radical, unsubstituted or mono- or polysubstituted aryl radical or heteroaryl radical having one or more five-, six- or seven-membered rings and * designates a chiral carbon atom preferably in the S or L configuration; or the acid addition salts thereof with organic and/or inorganic acids; and the use of the compounds of the general formulae (1) and (2) in medicine.

L~invention concerne des composés de formules générales (1) et (2) A - B - D - B' - A' (1) et A - B - D - E (2), dans lesquelles A et A' sont identiques ou différents et représentent le radical (I), X représentant S, O, CH2, CH2CH2, CH2O ou CH2NH, Y représentant H ou CN et * représentant un atome de carbone chiral de préférence de configuration S ou L ; B et B' sont identiques ou différents et représentent des radicaux alkyle, cycloalkyle, aralkyle, hétérocycloalkyle, hétéroarylalkyle, arylamidoalkyle ou hétéroaryamidoalkyle linéaires ou ramifiés, substitués ou non substitués, pouvant contenir un atome de O, N ou S, des radicaux aryle ou hétéroaryle non substitués ou comportant un ou plusieurs substituants et comportant un ou plusieurs cycles à cinq, six ou sept éléments ; D représente - S - S - ou - Se - Se - ; et E représente le groupement - CH2- CH (NH2) - R9 ou - CH2 - *CH (NH2) - R9, dans lequel R9 représente un radical alkyle, cycloalkyle, aralkyle, hétérocycloalkyle, hétéroarylalkyle, arylamidoalkyle ou hétéroaryamidoalkyle linéaire ou ramifié, substitué ou non substitué, pouvant contenir un atome de O, N ou S, un radical aryle ou hétéroaryle non substitué ou comportant un ou plusieurs substituants et comportant un ou plusieurs cycles à cinq, six ou sept éléments et * représente un atome de carbone chiral de préférence de configuration S ou L ; ou leurs sels d~addition acide avec des acides organiques et/ou inorganiques ; ainsi que l~utilisation des composés de formules générales (1) et (2) dans un médicament.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel dual-use peptidase inhibitors as prodrugs for a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel dual-use peptidase inhibitors as prodrugs for a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel dual-use peptidase inhibitors as prodrugs for a... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1695218

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.